Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Pathophysiology of ischemic stroke

INTRODUCTION

The term ischemic stroke is used to describe a variety of conditions in which blood flow to part or all of the brain is reduced, resulting in tissue damage. Although in some cases this may be a chronic condition, most strokes occur acutely. Research over the last four decades has resulted in a significant expansion of our knowledge and understanding of the molecular and cellular processes that underlie ischemia-induced cellular injury.

The goal of this review is to provide an overview of the underlying factors, such as the hemodynamic changes and molecular and cellular pathways, which are involved in stroke-related brain injury. A better understanding of these processes may help in the development of new therapies that are needed to treat this devastating disease.

STROKE SUBTYPES

The etiology and clinical classification of ischemic stroke subtypes is reviewed here briefly and discussed in greater detail separately. (See "Etiology, classification, and epidemiology of stroke", section on 'Brain ischemia' and "Clinical diagnosis of stroke subtypes".)

Acute ischemic stroke subtypes are often classified in clinical studies using a system developed by investigators of the TOAST trial, based upon the underlying cause (table 1) [1]. Under this system, strokes are classified into the following categories:

Large artery atherosclerosis

          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Nov 12, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24:35.
  2. Caplan LR. Basic pathology, anatomy, and pathophysiology of stroke. In: Caplan's Stroke: A Clinical Approach, 4th ed, Saunders Elsevier, Philadelphia 2009. p.22.
  3. Markus HS. Cerebral perfusion and stroke. J Neurol Neurosurg Psychiatry 2004; 75:353.
  4. Atkins ER, Brodie FG, Rafelt SE, et al. Dynamic cerebral autoregulation is compromised acutely following mild ischaemic stroke but not transient ischaemic attack. Cerebrovasc Dis 2010; 29:228.
  5. Aries MJ, Elting JW, De Keyser J, et al. Cerebral autoregulation in stroke: a review of transcranial Doppler studies. Stroke 2010; 41:2697.
  6. Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology 2010; 17:197.
  7. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 2008; 55:310.
  8. Douen AG, Akiyama K, Hogan MJ, et al. Preconditioning with cortical spreading depression decreases intraischemic cerebral glutamate levels and down-regulates excitatory amino acid transporters EAAT1 and EAAT2 from rat cerebal cortex plasma membranes. J Neurochem 2000; 75:812.
  9. Szatkowski M, Barbour B, Attwell D. Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake. Nature 1990; 348:443.
  10. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 2000; 403:316.
  11. Grewer C, Gameiro A, Zhang Z, et al. Glutamate forward and reverse transport: from molecular mechanism to transporter-mediated release after ischemia. IUBMB Life 2008; 60:609.
  12. Nandagopal K, Dawson TM, Dawson VL. Critical role for nitric oxide signaling in cardiac and neuronal ischemic preconditioning and tolerance. J Pharmacol Exp Ther 2001; 297:474.
  13. Lu GW, Liu HY. Downregulation of nitric oxide in the brain of mice during their hypoxic preconditioning. J Appl Physiol (1985) 2001; 91:1193.
  14. Bolaños JP, Almeida A. Roles of nitric oxide in brain hypoxia-ischemia. Biochim Biophys Acta 1999; 1411:415.
  15. Love S. Oxidative stress in brain ischemia. Brain Pathol 1999; 9:119.
  16. Mattson MP, Kroemer G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol Med 2003; 9:196.
  17. Leist M, Single B, Castoldi AF, et al. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997; 185:1481.
  18. Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol 2012; 69:576.
  19. del Zoppo GJ, Becker KJ, Hallenbeck JM. Inflammation after stroke: is it harmful? Arch Neurol 2001; 58:669.
  20. Macrez R, Ali C, Toutirais O, et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol 2011; 10:471.
  21. Snider BJ, Gottron FJ, Choi DW. Apoptosis and necrosis in cerebrovascular disease. Ann N Y Acad Sci 1999; 893:243.
  22. Ueda H, Fujita R. Cell death mode switch from necrosis to apoptosis in brain. Biol Pharm Bull 2004; 27:950.
  23. Back T, Hemmen T, Schüler OG. Lesion evolution in cerebral ischemia. J Neurol 2004; 251:388.
  24. Guglielmo MA, Chan PT, Cortez S, et al. The temporal profile and morphologic features of neuronal death in human stroke resemble those observed in experimental forebrain ischemia: the potential role of apoptosis. Neurol Res 1998; 20:283.
  25. Tarkowski E, Rosengren L, Blomstrand C, et al. Intrathecal expression of proteins regulating apoptosis in acute stroke. Stroke 1999; 30:321.
  26. Love S, Barber R, Wilcock GK. Neuronal death in brain infarcts in man. Neuropathol Appl Neurobiol 2000; 26:55.
  27. Sairanen T, Karjalainen-Lindsberg ML, Paetau A, et al. Apoptosis dominant in the periinfarct area of human ischaemic stroke--a possible target of antiapoptotic treatments. Brain 2006; 129:189.
  28. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999; 79:1431.
  29. Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008; 8:82.
  30. Simard JM, Kent TA, Chen M, et al. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 2007; 6:258.
  31. Klatzo I. Pathophysiological aspects of brain edema. Acta Neuropathol 1987; 72:236.
  32. Yang Y, Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 2011; 42:3323.
  33. Matarin M, Singleton A, Hardy J, Meschia J. The genetics of ischaemic stroke. J Intern Med 2010; 267:139.
  34. Carr FJ, McBride MW, Carswell HV, et al. Genetic aspects of stroke: human and experimental studies. J Cereb Blood Flow Metab 2002; 22:767.
  35. Bak S, Gaist D, Sindrup SH, et al. Genetic liability in stroke: a long-term follow-up study of Danish twins. Stroke 2002; 33:769.
  36. Seshadri S, Beiser A, Pikula A, et al. Parental occurrence of stroke and risk of stroke in their children: the Framingham study. Circulation 2010; 121:1304.
  37. Kasiman K, Lundholm C, Sandin S, et al. Familial effects on ischemic stroke: the role of sibling kinship, sex, and age of onset. Circ Cardiovasc Genet 2012; 5:226.
  38. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36:233.
  39. Zintzaras E, Rodopoulou P, Sakellaridis N. Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of stroke: a HuGE gene-disease association review and meta-analysis. Am J Epidemiol 2009; 169:523.
  40. Bevan S, Dichgans M, Gschwendtner A, et al. Variation in the PDE4D gene and ischemic stroke risk: a systematic review and meta-analysis on 5200 cases and 6600 controls. Stroke 2008; 39:1966.
  41. Newcombe PJ, Verzilli C, Casas JP, et al. Multilocus Bayesian meta-analysis of gene-disease associations. Am J Hum Genet 2009; 84:567.
  42. Traylor M, Farrall M, Holliday EG, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol 2012; 11:951.
  43. Damani SB, Topol EJ. Molecular genetics of atrial fibrillation. Genome Med 2009; 1:54.
  44. Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet 2009; 41:876.
  45. International Stroke Genetics Consortium (ISGC), Wellcome Trust Case Control Consortium 2 (WTCCC2), Bellenguez C, et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet 2012; 44:328.
  46. Gschwendtner A, Bevan S, Cole JW, et al. Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann Neurol 2009; 65:531.
  47. Kubo M, Hata J, Ninomiya T, et al. A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat Genet 2007; 39:212.
  48. Williams FM, Carter AM, Hysi PG, et al. Ischemic stroke is associated with the ABO locus: the EuroCLOT study. Ann Neurol 2013; 73:16.
  49. Schilling S, DeStefano AL, Sachdev PS, et al. APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis. Neurology 2013; 81:292.
  50. Rastenyte D, Tuomilehto J, Sarti C. Genetics of stroke--a review. J Neurol Sci 1998; 153:132.
  51. Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005; 37:435.
  52. Ballabio E, Bersano A, Bresolin N, Candelise L. Monogenic vessel diseases related to ischemic stroke: a clinical approach. J Cereb Blood Flow Metab 2007; 27:1649.
  53. Onodera O, Nozaki H, Fukutake T. CARASIL. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK32533/ (Accessed on May 03, 2011).
  54. Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 1997; 49:1322.
  55. Ophoff RA, DeYoung J, Service SK, et al. Hereditary vascular retinopathy, cerebroretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy, and stroke map to a single locus on chromosome 3p21.1-p21.3. Am J Hum Genet 2001; 69:447.
  56. Lanktree MB, Dichgans M, Hegele RA. Advances in genomic analysis of stroke: what have we learned and where are we headed? Stroke 2010; 41:825.